deltatrials
Completed PHASE3 NCT00212355

Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.

Phase3, Open-Label, Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.

Sponsor: Nobelpharma

Interventions NPC-02
Updated 7 times since 2017 Last updated: Feb 18, 2025 Started: Mar 31, 2005 Primary completion: Apr 30, 2008 Completion: Jan 31, 2009

This PHASE3 trial investigates Wilson's Disease and is currently completed. Nobelpharma leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~May 2019 · 11 months · monthly snapshotCompleted~May 2019 – ~Jan 2021 · 20 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshotCompleted~Apr 2025 – present · 12 months · monthly snapshotCompleted

Change History

7 versions recorded
  1. Apr 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. May 2019 — Jan 2021 [monthly]

    Completed PHASE3

Show 2 earlier versions
  1. Jun 2018 — May 2019 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Nobelpharma
Data source: Nobelpharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.